Does Novartis really love lentiviral?
The company is rumoured to be pursuing Avrobio, which would be a bargain even by gene therapy standards.
A renewed push into early bladder cancer
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
Xylocor sees enough to press on with angina gene therapy
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
Rocket is bringing lenti back
The gene therapy player survived 2022 relatively unscathed, but big tests remain.